Cargando…
Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection
SARS-CoV-2 infection is generally mild or asymptomatic in children but a biological basis for this outcome is unclear. Here we compare antibody and cellular immunity in children (aged 3–11 years) and adults. Antibody responses against spike protein were high in children and seroconversion boosted re...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709786/ https://www.ncbi.nlm.nih.gov/pubmed/34937928 http://dx.doi.org/10.1038/s41590-021-01089-8 |
_version_ | 1784623019796201472 |
---|---|
author | Dowell, Alexander C. Butler, Megan S. Jinks, Elizabeth Tut, Gokhan Lancaster, Tara Sylla, Panagiota Begum, Jusnara Bruton, Rachel Pearce, Hayden Verma, Kriti Logan, Nicola Tyson, Grace Spalkova, Eliska Margielewska-Davies, Sandra Taylor, Graham S. Syrimi, Eleni Baawuah, Frances Beckmann, Joanne Okike, Ifeanyichukwu O. Ahmad, Shazaad Garstang, Joanna Brent, Andrew J. Brent, Bernadette Ireland, Georgina Aiano, Felicity Amin-Chowdhury, Zahin Jones, Samuel Borrow, Ray Linley, Ezra Wright, John Azad, Rafaq Waiblinger, Dagmar Davis, Chris Thomson, Emma C. Palmarini, Massimo Willett, Brian J. Barclay, Wendy S. Poh, John Amirthalingam, Gayatri Brown, Kevin E. Ramsay, Mary E. Zuo, Jianmin Moss, Paul Ladhani, Shamez |
author_facet | Dowell, Alexander C. Butler, Megan S. Jinks, Elizabeth Tut, Gokhan Lancaster, Tara Sylla, Panagiota Begum, Jusnara Bruton, Rachel Pearce, Hayden Verma, Kriti Logan, Nicola Tyson, Grace Spalkova, Eliska Margielewska-Davies, Sandra Taylor, Graham S. Syrimi, Eleni Baawuah, Frances Beckmann, Joanne Okike, Ifeanyichukwu O. Ahmad, Shazaad Garstang, Joanna Brent, Andrew J. Brent, Bernadette Ireland, Georgina Aiano, Felicity Amin-Chowdhury, Zahin Jones, Samuel Borrow, Ray Linley, Ezra Wright, John Azad, Rafaq Waiblinger, Dagmar Davis, Chris Thomson, Emma C. Palmarini, Massimo Willett, Brian J. Barclay, Wendy S. Poh, John Amirthalingam, Gayatri Brown, Kevin E. Ramsay, Mary E. Zuo, Jianmin Moss, Paul Ladhani, Shamez |
author_sort | Dowell, Alexander C. |
collection | PubMed |
description | SARS-CoV-2 infection is generally mild or asymptomatic in children but a biological basis for this outcome is unclear. Here we compare antibody and cellular immunity in children (aged 3–11 years) and adults. Antibody responses against spike protein were high in children and seroconversion boosted responses against seasonal Beta-coronaviruses through cross-recognition of the S2 domain. Neutralization of viral variants was comparable between children and adults. Spike-specific T cell responses were more than twice as high in children and were also detected in many seronegative children, indicating pre-existing cross-reactive responses to seasonal coronaviruses. Importantly, children retained antibody and cellular responses 6 months after infection, whereas relative waning occurred in adults. Spike-specific responses were also broadly stable beyond 12 months. Therefore, children generate robust, cross-reactive and sustained immune responses to SARS-CoV-2 with focused specificity for the spike protein. These findings provide insight into the relative clinical protection that occurs in most children and might help to guide the design of pediatric vaccination regimens. |
format | Online Article Text |
id | pubmed-8709786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-87097862022-01-10 Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection Dowell, Alexander C. Butler, Megan S. Jinks, Elizabeth Tut, Gokhan Lancaster, Tara Sylla, Panagiota Begum, Jusnara Bruton, Rachel Pearce, Hayden Verma, Kriti Logan, Nicola Tyson, Grace Spalkova, Eliska Margielewska-Davies, Sandra Taylor, Graham S. Syrimi, Eleni Baawuah, Frances Beckmann, Joanne Okike, Ifeanyichukwu O. Ahmad, Shazaad Garstang, Joanna Brent, Andrew J. Brent, Bernadette Ireland, Georgina Aiano, Felicity Amin-Chowdhury, Zahin Jones, Samuel Borrow, Ray Linley, Ezra Wright, John Azad, Rafaq Waiblinger, Dagmar Davis, Chris Thomson, Emma C. Palmarini, Massimo Willett, Brian J. Barclay, Wendy S. Poh, John Amirthalingam, Gayatri Brown, Kevin E. Ramsay, Mary E. Zuo, Jianmin Moss, Paul Ladhani, Shamez Nat Immunol Article SARS-CoV-2 infection is generally mild or asymptomatic in children but a biological basis for this outcome is unclear. Here we compare antibody and cellular immunity in children (aged 3–11 years) and adults. Antibody responses against spike protein were high in children and seroconversion boosted responses against seasonal Beta-coronaviruses through cross-recognition of the S2 domain. Neutralization of viral variants was comparable between children and adults. Spike-specific T cell responses were more than twice as high in children and were also detected in many seronegative children, indicating pre-existing cross-reactive responses to seasonal coronaviruses. Importantly, children retained antibody and cellular responses 6 months after infection, whereas relative waning occurred in adults. Spike-specific responses were also broadly stable beyond 12 months. Therefore, children generate robust, cross-reactive and sustained immune responses to SARS-CoV-2 with focused specificity for the spike protein. These findings provide insight into the relative clinical protection that occurs in most children and might help to guide the design of pediatric vaccination regimens. Nature Publishing Group US 2021-12-22 2022 /pmc/articles/PMC8709786/ /pubmed/34937928 http://dx.doi.org/10.1038/s41590-021-01089-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Dowell, Alexander C. Butler, Megan S. Jinks, Elizabeth Tut, Gokhan Lancaster, Tara Sylla, Panagiota Begum, Jusnara Bruton, Rachel Pearce, Hayden Verma, Kriti Logan, Nicola Tyson, Grace Spalkova, Eliska Margielewska-Davies, Sandra Taylor, Graham S. Syrimi, Eleni Baawuah, Frances Beckmann, Joanne Okike, Ifeanyichukwu O. Ahmad, Shazaad Garstang, Joanna Brent, Andrew J. Brent, Bernadette Ireland, Georgina Aiano, Felicity Amin-Chowdhury, Zahin Jones, Samuel Borrow, Ray Linley, Ezra Wright, John Azad, Rafaq Waiblinger, Dagmar Davis, Chris Thomson, Emma C. Palmarini, Massimo Willett, Brian J. Barclay, Wendy S. Poh, John Amirthalingam, Gayatri Brown, Kevin E. Ramsay, Mary E. Zuo, Jianmin Moss, Paul Ladhani, Shamez Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection |
title | Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection |
title_full | Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection |
title_fullStr | Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection |
title_full_unstemmed | Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection |
title_short | Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection |
title_sort | children develop robust and sustained cross-reactive spike-specific immune responses to sars-cov-2 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709786/ https://www.ncbi.nlm.nih.gov/pubmed/34937928 http://dx.doi.org/10.1038/s41590-021-01089-8 |
work_keys_str_mv | AT dowellalexanderc childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT butlermegans childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT jinkselizabeth childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT tutgokhan childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT lancastertara childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT syllapanagiota childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT begumjusnara childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT brutonrachel childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT pearcehayden childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT vermakriti childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT logannicola childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT tysongrace childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT spalkovaeliska childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT margielewskadaviessandra childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT taylorgrahams childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT syrimieleni childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT baawuahfrances childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT beckmannjoanne childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT okikeifeanyichukwuo childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT ahmadshazaad childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT garstangjoanna childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT brentandrewj childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT brentbernadette childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT irelandgeorgina childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT aianofelicity childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT aminchowdhuryzahin childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT jonessamuel childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT borrowray childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT linleyezra childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT wrightjohn childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT azadrafaq childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT waiblingerdagmar childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT davischris childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT thomsonemmac childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT palmarinimassimo childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT willettbrianj childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT barclaywendys childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT pohjohn childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT amirthalingamgayatri childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT brownkevine childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT ramsaymarye childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT zuojianmin childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT mosspaul childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection AT ladhanishamez childrendeveloprobustandsustainedcrossreactivespikespecificimmuneresponsestosarscov2infection |